Deucravacitinib for Pediatric Plaque Psoriasis

We are studying a new medication for children and teens with moderate to severe plaque psoriasis. The trial will help us understand how well it works and its safety compared to a placebo.

1-2 yearsConfirmation phase (III)Post-Trial Drug AccessCost ReimbursementPartially RemoteStandard MedicinesOralDermatologyPediatrics

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Deucravacitinib
Deucravacitinib is a substance that blocks a specific immune enzyme to lower inflammation, mainly used for moderate-to-severe plaque psoriasis.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Dr Jean Eric Techer
Dermatology
Coulogne, France
Centre Hospitalier Universitaire De Nice
Dermatology
Nice, France
Centre Hospitalier Universitaire De Dijon
Dermatology
Saint-Apollinaire, France
Sponsor: Bristol-Myers Squibb Services Unlimited Company
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.